Articles

These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months. Read More ›

This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 10⁹/L from week 12 onward and no new safety signals observed during the study period. Read More ›

Treatment of patients with relapsed/refractory or symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL) with the combination of acalabrutinib and obinutuzumab resulted in an acceptable safety profile and a >90% overall response rate, with 8% to 16% complete responses, and a median progression-free survival that was not reached at a median follow-up of 18 to 21 months. Read More ›

In a retrospective cohort analysis of the largest series of patients with mantle-cell lymphoma (MCL) in which real-world economic burden data have been reported, the substantial economic burden of MCL was quantified, with inpatient admissions and office visits as the largest drivers of total costs for patients treated with rituximab, cyclophosphamide, doxorubicin, and vincristine; bendamustine and rituximab; and rituximab, and prescription drug costs as the largest component of total costs for patients receiving ibrutinib. Read More ›

In a single-center, open-label, nonrandomized phase 2 study, the combination of pembrolizumab and rituximab was shown to be safe and effective (64% overall response rate, with a 48% complete response rate) in treating relapsed follicular lymphoma (FL); however, efficacy appeared to be unrelated to PD-L1 expression. Read More ›

In patients with relapsed chronic lymphocytic leukemia (CLL), first salvage therapy with bendamustine and rituximab resulted in a 12-month progression-free survival (PFS) of 81% and overall survival (OS) of 92%, but PFS and OS were significantly lower in patients with del(17p) and/or unmutated IGHV and advanced stage disease (ie, Rai III-IV or Binet C). Read More ›

At a median follow-up of 6 months, the triplet combination of umbralisib, ublituximab, and pembrolizumab was well-tolerated, with durable responses in patients with chronic lymphocytic leukemia (CLL) refractory to Bruton’s tyrosine kinase inhibitor therapy. Read More ›

The addition of rituximab to ibrutinib in relapsed and high-risk treatment-naïve patients with chronic lymphocytic leukemia (CLL) did not improve progression-free survival, but patients treated with the combination reached their remissions significantly faster and achieved lower minimal residual disease levels, suggesting that single-agent ibrutinib should remain as the standard-of-care therapy in CLL, but the addition of rituximab can be considered in high-risk patients in whom a faster response is desirable. Read More ›

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab used as first-line treatment in patients with chronic lymphocytic leukemia (CLL) with mutated IGHV achieves a high rate of undetectable minimal residual disease and complete remission after 3 courses, with an acceptable safety profile. Read More ›

The combination of ibrutinib and venetoclax is safe and effective in patients with chronic lymphocytic leukemia (CLL), with a 100% overall response rate and acceptable toxicities. Read More ›